Caseware UK (AP4) 2024.0.164 2024.0.164 2024-05-012024-05-012024-05-01falsefalse592024-01-01No description of principal activity72false 02856632 2024-01-01 2024-12-31 02856632 2023-01-01 2023-12-31 02856632 2024-12-31 02856632 2023-12-31 02856632 2023-01-01 02856632 1 2024-01-01 2024-12-31 02856632 1 2023-01-01 2023-12-31 02856632 3 2024-01-01 2024-12-31 02856632 3 2023-01-01 2023-12-31 02856632 4 2024-01-01 2024-12-31 02856632 4 2023-01-01 2023-12-31 02856632 5 2024-01-01 2024-12-31 02856632 5 2023-01-01 2023-12-31 02856632 d:CompanySecretary1 2024-01-01 2024-12-31 02856632 d:Director1 2024-01-01 2024-12-31 02856632 d:Director2 2024-01-01 2024-12-31 02856632 d:Director2 2024-12-31 02856632 d:Director3 2024-01-01 2024-12-31 02856632 d:Director3 2024-12-31 02856632 d:RegisteredOffice 2024-01-01 2024-12-31 02856632 e:Buildings e:LongLeaseholdAssets 2024-01-01 2024-12-31 02856632 e:Buildings e:LongLeaseholdAssets 2024-12-31 02856632 e:Buildings e:LongLeaseholdAssets 2023-12-31 02856632 e:PlantMachinery 2024-01-01 2024-12-31 02856632 e:PlantMachinery 2024-12-31 02856632 e:PlantMachinery 2023-12-31 02856632 e:PlantMachinery e:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 02856632 e:MotorVehicles 2024-01-01 2024-12-31 02856632 e:MotorVehicles 2024-12-31 02856632 e:MotorVehicles 2023-12-31 02856632 e:MotorVehicles e:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 02856632 e:FurnitureFittings 2024-01-01 2024-12-31 02856632 e:FurnitureFittings 2024-12-31 02856632 e:FurnitureFittings 2023-12-31 02856632 e:FurnitureFittings e:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 02856632 e:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 02856632 e:PatentsTrademarksLicencesConcessionsSimilar 2024-01-01 2024-12-31 02856632 e:ComputerSoftware 2024-12-31 02856632 e:ComputerSoftware 2023-12-31 02856632 e:CurrentFinancialInstruments 2024-12-31 02856632 e:CurrentFinancialInstruments 2023-12-31 02856632 e:CurrentFinancialInstruments e:WithinOneYear 2024-12-31 02856632 e:CurrentFinancialInstruments e:WithinOneYear 2023-12-31 02856632 f:UnitedKingdom 2024-01-01 2024-12-31 02856632 f:UnitedKingdom 2023-01-01 2023-12-31 02856632 f:RestEuropeOutsideUK 2024-01-01 2024-12-31 02856632 f:RestEuropeOutsideUK 2023-01-01 2023-12-31 02856632 f:RestWorldOutsideUK 2024-01-01 2024-12-31 02856632 f:RestWorldOutsideUK 2023-01-01 2023-12-31 02856632 e:UKTax 2024-01-01 2024-12-31 02856632 e:UKTax 2023-01-01 2023-12-31 02856632 e:ForeignTax 2024-01-01 2024-12-31 02856632 e:ForeignTax 2023-01-01 2023-12-31 02856632 e:ShareCapital 2024-12-31 02856632 e:ShareCapital 2023-01-01 2023-12-31 02856632 e:ShareCapital 2023-12-31 02856632 e:ShareCapital 2023-01-01 02856632 e:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 02856632 e:RetainedEarningsAccumulatedLosses 2024-12-31 02856632 e:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 02856632 e:RetainedEarningsAccumulatedLosses 2023-12-31 02856632 e:RetainedEarningsAccumulatedLosses 2023-01-01 02856632 e:AcceleratedTaxDepreciationDeferredTax 2024-12-31 02856632 e:AcceleratedTaxDepreciationDeferredTax 2023-12-31 02856632 e:TaxLossesCarry-forwardsDeferredTax 2024-12-31 02856632 e:TaxLossesCarry-forwardsDeferredTax 2023-12-31 02856632 e:OtherDeferredTax 2024-12-31 02856632 e:OtherDeferredTax 2023-12-31 02856632 d:OrdinaryShareClass1 2024-01-01 2024-12-31 02856632 d:OrdinaryShareClass1 2024-12-31 02856632 d:FRS102 2024-01-01 2024-12-31 02856632 d:Audited 2024-01-01 2024-12-31 02856632 d:FullAccounts 2024-01-01 2024-12-31 02856632 d:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 02856632 e:Subsidiary1 2024-01-01 2024-12-31 02856632 e:Subsidiary1 1 2024-01-01 2024-12-31 02856632 e:WithinOneYear 2024-12-31 02856632 e:WithinOneYear 2023-12-31 02856632 e:BetweenOneFiveYears 2024-12-31 02856632 e:BetweenOneFiveYears 2023-12-31 02856632 e:ComputerSoftware e:InternallyGeneratedIntangibleAssets 2024-01-01 2024-12-31 02856632 6 2024-01-01 2024-12-31 02856632 e:ComputerSoftware e:OwnedIntangibleAssets 2024-01-01 2024-12-31 02856632 g:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 02856632









Apollo Scientific Ltd









Annual report and financial statements

For the year ended 31 December 2024

 
Apollo Scientific Ltd
 
 
Company Information


Directors
H Honjo 
K Miyauchi (appointed 1 May 2024)




Company secretary
J A Hobday



Registered number
02856632



Registered office
Unit 3 & 4 Parkway
Denton

Manchester

M34 3SG




Independent auditors
Hurst Accountants Limited
Chartered Accountants & Statutory Auditors

3 Stockport Exchange

Stockport

Cheshire

SK1 3GG





 
Apollo Scientific Ltd
 

Contents



Page
Strategic report
 
1 - 2
Directors' report
 
3 - 4
Independent auditors' report
 
5 - 8
Statement of comprehensive income
 
9
Balance sheet
 
10
Statement of changes in equity
 
11
Statement of cash flows
 
12
Analysis of net debt
 
13
Notes to the financial statements
 
14 - 28


 
Apollo Scientific Ltd
 
 
Strategic report
For the year ended 31 December 2024

Introduction
 
The directors present the strategic report for the year ended 31 December 2024.

Business review
 
The results for the period were considered disappointing by the directors with an operating loss of £759k recorded, however the overall financial position remains strong with cash reserves of £4.0m.
  
Turnover decreased by £1.8m to £9.5m (16%) when compared to the prior year. This was largely attributed to continuing poor market conditions, as a result of continuing inflationary pressures impacting worldwide economies particularly within the local UK market, resulting in a large double digit decrease within the bulk side of the business, especially within the pharmaceutical sector. The company are looking to expand commercial activities within the broader industrial chemicals sector to reduce reliance on pharmaceutical business. Catalogue business also showed a single digit decline on the prior year due to both decreased spending budgets at key clients and increasing competition from overseas competitors. The company are responding to this through continuing adaption of its product range and placing more focus on moving into new product lines with less competition and offering a more complete laboratory product and service solution to its customer base. 
The directors were pleased to report that, despite ongoing issues as a result of Brexit, the EU market remained consistent with prior year’s sales and the company hope to further capitalise on this through the now established subsidiary company Apollo Scientific GmbH (Germany) and development of EU stock location in 2025.
Gross profit % increased slightly by 2% to 35.6% as a result of a higher proportion of sales coming from higher margin catalogue business. 
Overheads reduced by £504k (11%) compared to previous year, largely due to a reduction in staff numbers most notably within production and some administrative areas.
The directors and executive management team expect to see an improvement in turnover and return to profitability in the near future through expanding business development resource and increasing profile in non-pharmaceutical sectors to develop more stable demand bulk projects. The company remains committed to achieving long term stability through achieving higher throughput within the catalogue business and considerably reducing the current cost to process an order by continuing to prioritise investment within IT and automation projects to improve efficiency and reduce labour demands in this area. Investment within automated carousel stocking machines have assisted in improving warehouse efficiency and reduce warehouse footprint which has enabled the company to consolidate all operations onto one site from the beginning of 2025. This is anticipated to help improve communication and further streamline processes and develop efficiencies to ultimately drive profitability within the catalogue business.

Page 1

 
Apollo Scientific Ltd
 

Strategic report (continued)
For the year ended 31 December 2024

Principal risks and uncertainties
 
The company trades in overseas markets. Both sales and purchases are made in foreign currencies therefore a natural hedge exists to an extent. Prices are constantly monitored and where unfavourable exchange rate movements are expected, are altered accordingly where possible. 
Credit risk is managed by standard procedures including the use of credit rating agencies when deciding upon credit terms and the ongoing monitoring of accounts. Liquidity risk is managed by keeping sufficient cash deposits in order to meet liabilities as they fall due.
The company sells into a range of different markets across the international stage and is therefore exposed to risks associated with declining economies within these markets. This is offset to some extent by trading to a number of different countries and industrial sectors however the company are working to reduce reliance on the pharmaceutical sector which had accounted for a large proportion of bulk sales within recent years.
 
Operating within the chemical industry, the company is subject to a number of laws and regulations and remain at risk to changing legislation which could impact ability to trade in certain product lines or markets. This can impact both product sales and overheads through increasing cost of compliance. 

Financial key performance indicators
 
A summary of the financial key performance indicators for the past five years is as follows:


2024
2023
2022
2021
2020






Turnover £'000
9,500
11,277
13,704
13,939
15,307
Gross profit £'000
3,383
3,722
4,980
5,449
5,714
Gross profit %
35.6%
33.0%
36.3%
39.1%
37.3%
(Loss)/Profit before tax £'000
(689)
(915)
873
1,172
1,873
(Loss)/Profit before tax %
(7%)
(8%)
6%
8%
12%
No. of employees
59
72
76
76
71
Turnover/ employee £'000
161
157
180
183
216
Gross profit/ employee £'000
57
52
66
72
80
(Loss)/Profit before tax/ employee £'000
(12)
(13)
11
15
26



This report was approved by the board and signed on its behalf.




K Miyauchi
Director

Date: 7 February 2025

Page 2

 
Apollo Scientific Ltd
 
 
 
Directors' report
For the year ended 31 December 2024

The directors present their report and the financial statements for the year ended 31 December 2024.

Directors' responsibilities statement

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

 In preparing these financial statements, the directors are required to:


select suitable accounting policies for the company's financial statements and then apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The loss for the year, after taxation, amounted to £412,954 (2023 -loss £788,601).

Dividends declared in the year amount to £Nil (2023- £Nil).

Directors

The directors who served during the year were:

H Honjo 
K Miyauchi (appointed 1 May 2024)
T Kawano (resigned 1 May 2024)

Future developments

The company is focusing on building a sustainable long term model for its catalogue business through developing processes to reduce the cost to service an order by investing in technology to introduce more automation into processes and continues to explore ways to create streamlined and efficient working methods, alongside improving access for international markets through establishment of overseas subsidiaries and stocking locations in order to increase market share. The company is working on ways to improve access to inventory through exploring strategic partnerships with third parties to assist with this as well as developing higher value product lines with less competition. 

Page 3

 
Apollo Scientific Ltd
 
 
 
Directors' report (continued)
For the year ended 31 December 2024

Research and development activities

The company continues to invest in research and development to increase in-house production capabilities in order to enable fulfilment of more client custom projects and increase the number of novel higher value products being brought to market.
Accreditations 
The company is committed to ensuring it conducts all its activities in full compliance with all laws and regulations whilst maintaining a high ethical and social standing with great emphasis placed on environmental, social and governance (ESG) principles.
The company produces an annual CSR report and continues to lead the way within its sector being one of few to hold the EcoVadis Platinum award for corporate sustainability, a medal held since 2020, placing it within the top 1% of companies assessed within the sector. The company remains signatories to the UN Global Compact, reporting an annual Communication of Progress, and has maintained its ISO 9001:2015 and 12001:2015 accreditations along with holding Known Consignor and Authorised Economic Operator status. 

Matters covered in the Strategic report

The principal risks and uncertainties including reference to financial instruments are included in the strategic report.

Disclosure of information to auditors

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:
 
so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware, and

the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Post balance sheet events

There have been no significant events affecting the company since the year end.

Auditors

The auditorsHurst Accountants Limitedwill be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 




K Miyauchi
Director

Date: 7 February 2025

Page 4

 
Apollo Scientific Ltd
 
 
 
Independent auditors' report to the members of Apollo Scientific Ltd
 

Opinion


We have audited the financial statements of Apollo Scientific Ltd (the 'company') for the year ended 31 December 2024, which comprise the Statement of comprehensive income, the Balance sheet, the Statement of cash flows, the Statement of changes in equity and the related notes, including a summary of significant accounting policiesThe financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Other information


The other information comprises the information included in the annual report other than the financial statements and our Auditors' report thereon. The directors are responsible for the other information contained within the annual reportOur opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Page 5

 
Apollo Scientific Ltd
 
 
 
Independent auditors' report to the members of Apollo Scientific Ltd (continued)


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.


Responsibilities of directors
 

As explained more fully in the Directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.


Page 6

 
Apollo Scientific Ltd
 
 
 
Independent auditors' report to the members of Apollo Scientific Ltd (continued)


Auditors' responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 
Identifying and assessing potential risks related to irregularities
In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:
 
The nature of the industry and sector, control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets.
Enquiring of local management and parent company management, including obtaining and reviewing supporting documentation, concerning the company's policies and procedures relating to:
°Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
°Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected of alleged fraud;
The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
Discussing among the engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud;
Obtaining an understanding of the legal and regulatory frameworks that the Company operates in, focusing on those laws and regulations that had a direct effect on the financial statements,  such as the Companies Act 2006, pensions and tax legislation, or that had a fundamental effect on the operations of the Company, including General Data Protection requirements, Anti-bribery and Health & Safety. 

Audit response to risks identified
Our procedures to respond to risk identified included the following:
Reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;
Evaluation of management’s controls designed to prevent and detect irregularities;
Enquiring of management concerning actual and potential litigation and claims;
Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
Reading minutes of meetings of those charged with governance and correspondence with regulators. 

Page 7

 
Apollo Scientific Ltd
 
 
 
Independent auditors' report to the members of Apollo Scientific Ltd (continued)


We have also considered the risks noted above in addressing the risk of fraud through management override of controls:
 
Testing the appropriateness of journal entries and other adjustments; we have used data analytics software to runs tests designed to identify accounting transactions which may pose a heightened risk of material misstatement, whether due to fraud or error.
Challenging assumptions made by management in their significant accounting estimates, and assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and
Evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
 
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.
There are inherent limitations in the audit procedures described above, and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.  Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.


Use of our report
 

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.





Chris Stewardson (Senior statutory auditor)
for and on behalf of
Hurst Accountants Limited
Chartered Accountants
Statutory Auditors
3 Stockport Exchange
Stockport
Cheshire
SK1 3GG

7 February 2025
Page 8

 
Apollo Scientific Ltd
 
 
Statement of comprehensive income
For the year ended 31 December 2024

2024
2023
Note
£
£

  

Turnover
 4 
9,499,819
11,277,094

Cost of sales
  
(6,117,163)
(7,555,506)

Gross profit
  
3,382,656
3,721,588

Administrative expenses
  
(4,185,532)
(4,689,213)

Other operating income
 5 
44,319
-

Operating loss
 6 
(758,557)
(967,625)

Interest receivable and similar income
 9 
77,721
52,698

Loss before tax
  
(680,836)
(914,927)

Tax on loss
 10 
267,882
126,326

Loss for the financial year
  
(412,954)
(788,601)

There was no other comprehensive income for 2024 (2023:£NIL).

The notes on pages 14 to 28 form part of these financial statements.

Page 9

 
Apollo Scientific Ltd
Registered number: 02856632

Balance sheet
As at 31 December 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 12 
203,731
140,358

Tangible assets
 11 
1,245,913
398,164

Investments
 13 
21,373
-

  
1,471,017
538,522

Current assets
  

Stocks
 14 
5,414,334
5,770,416

Debtors: amounts falling due within one year
 15 
2,123,716
2,492,363

Cash at bank and in hand
 16 
4,006,429
5,190,074

  
11,544,479
13,452,853

Creditors: amounts falling due within one year
 17 
(1,163,191)
(1,648,402)

Net current assets
  
 
 
10,381,288
 
 
11,804,451

Total assets less current liabilities
  
11,852,305
12,342,973

Provisions for liabilities
  

Deferred tax
 18 
-
(77,714)

Net assets
  
11,852,305
12,265,259


Capital and reserves
  

Called up share capital 
 19 
99
99

Profit and loss account
 20 
11,852,206
12,265,160

  
11,852,305
12,265,259


The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




K Miyauchi
Director

Date: 7 February 2025

The notes on pages 14 to 28 form part of these financial statements.

Page 10

 
Apollo Scientific Ltd
 

Statement of changes in equity
For the year ended 31 December 2024


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 January 2023
99
13,053,761
13,053,860


Comprehensive income for the year

Loss for the year
-
(788,601)
(788,601)
Total comprehensive income for the year
-
(788,601)
(788,601)



At 1 January 2024
99
12,265,160
12,265,259


Comprehensive income for the year

Loss for the year
-
(412,954)
(412,954)


At 31 December 2024
99
11,852,206
11,852,305


Page 11

 
Apollo Scientific Ltd
 

Statement of cash flows
For the year ended 31 December 2024

2024
2023
£
£

Cash flows from operating activities

Loss for the financial year
(412,954)
(788,601)

Adjustments for:

Amortisation of intangible assets
77,842
49,599

Depreciation of tangible assets
233,341
258,650

Interest received
(77,721)
(52,698)

Taxation charge
(267,882)
(126,326)

Decrease in stocks
356,082
124,845

Decrease/(increase) in debtors
257,449
(152,706)

(Increase)/decrease in amounts owed by groups
(33,169)
1,596

(Decrease)/increase in creditors
(337,040)
169,168

(Decrease)/increase in amounts owed to groups
(148,171)
107,294

Corporation tax received/(paid)
334,535
(32,250)

(Profit)/Loss on disposal of intangible
-
(15,066)

Net cash generated from operating activities

(17,688)
(456,495)


Cash flows from investing activities

Purchase of intangible fixed assets
(141,215)
(72,024)

Sale of intangible assets
-
15,066

Purchase of tangible fixed assets
(1,081,090)
(49,932)

Purchase of fixed asset investments
(21,373)
-

Interest received
77,721
52,698

Net cash from investing activities

(1,165,957)
(54,192)

Cash flows from financing activities

Dividends paid
-
(102,396)

Net cash used in financing activities
-
(102,396)

Net (decrease) in cash and cash equivalents
(1,183,645)
(613,083)

Cash and cash equivalents at beginning of year
5,190,074
5,803,157

Cash and cash equivalents at the end of year
4,006,429
5,190,074


Cash and cash equivalents at the end of year comprise:

Cash at bank and in hand
4,006,429
5,190,074

4,006,429
5,190,074


The notes on pages 14 to 28 form part of these financial statements.

Page 12

 
Apollo Scientific Ltd
 

Analysis of Net Debt
For the year ended 31 December 2024




At 1 January 2024
Cash flows
At 31 December 2024
£

£

£

Cash at bank and in hand

5,190,074

(1,183,645)

4,006,429


5,190,074
(1,183,645)
4,006,429

The notes on pages 14 to 28 form part of these financial statements.

Page 13

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

1.


General information

Apollo Scientific Limited is a private company limited by share capital incorporated in England, registered number 02856632. The address of the registered office and principal place of business is Unit 3&4 Parkway, Denton, Manchester, England, M34 3SG.
The nature of the company's operation and its principal activity is that of the supply of chemicals and other related products. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors have prepared the financial statements on a going concern basis which assumes the company will have sufficient reserves to meet liabilities as they fall due.
During the year ended 31 December 2024, the company reported losses of £412,954 (
2023: £788,601) and net assets of £11,852,305 (2023: £12,265,259) and cash reserves of £4,006,429 (2023: £5,190,074) at 31 December 2024.
The directors have prepared forecasts for the next financial year which show a growth in sales and a significantly smaller loss is expected. The Senior Management Team remain confident that 2025 budgets will be met considering the strong backorders position as at end January 2025 and given the significant cash reserves and net asset position, the directors have no concerns over meeting liabilities as they fall due

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the company has transferred the significant risks and rewards of ownership to the buyer;
the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Page 14

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

2.Accounting policies (continued)

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property
-
5 - 12.5% straight line over the life of the lease
Plant and machinery
-
12.5% straight line
Motor vehicles
-
20% straight line
Fixtures, fittings and equipment
-
10 - 33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 The estimated useful lives range as follows:

Computer Software
-
5
years

 
2.6

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

Page 15

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

2.Accounting policies (continued)

 
2.7

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.8

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable.
Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. 
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.


For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.
Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 
2.9

Operating leases: the company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 16

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

2.Accounting policies (continued)

 
2.10

Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.

 
2.11

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

  
2.12

Research and development

Research and development costs are written off in the period they are incurred.

 
2.13

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

Page 17

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

2.Accounting policies (continued)

 
2.14

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.15

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

In the Statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the company's cash management.

 
2.16

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.17

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 18

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

3.


Judgements in applying accounting policies and key sources of estimation uncertainty

Management discussed with the directors the development, selection and disclosure of the company's critical accounting policies and estimates and the application of these policies and estimates. The key sources of estimation, uncertainty and critical accounting judgements in applying the company's policies are discussed below.
Provision for impairment loss on trade receivables
The management of the company exercises significant judgement in providing for impairment loss on trade receivables. Should these estimates vary, the profit or loss and balance sheet of the following years could be significantly impacted. The carrying value of trade receivables was £1,489,451 (2023 - £1,734,104). 
Provision for obsolete and slow moving stocks
The company reviews its stocks to assess loss on account of obsolescence on a regular basis. In determining whether provision for obsolescence should be recorded in profit or loss, the company makes judgements as to whether there is any observable data indicating that there is any future saleability of the product and the estimated net realisable value for such product. Accordingly, provision for impairment is made where the net realisable value is less than the cost based on best estimates by the management. The provision for obsolescence of stock is based on the ageing and historical sales pattern. The carrying value of stocks was £5,414,334 (2023 - £5,770,416).


4.


Turnover

Analysis of turnover by country of destination:

2024
2023
£
£

United Kingdom
2,225,261
2,773,794

Rest of Europe
3,923,594
4,172,460

Rest of the world
3,350,964
4,330,840

9,499,819
11,277,094



5.


Other operating income

2024
2023
£
£

Sundry income
44,319
-


Page 19

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

6.


Operating loss


The operating loss is stated after charging:

2024
2023
£
£

Research & development charged as an expense
400,000
455,824

Exchange differences
61,341
113,033

Other operating lease rentals
288,207
282,440

During the year, no director received any emoluments (2023 - £Nil).


7.


Auditors' remuneration

During the year, the company obtained the following services from the company's auditors and their associates:


2024
2023
£
£

Fees payable to the company's auditors and their associates for the audit of the company's financial statements
14,600
13,150

Fees payable to the company's auditors and their associates in respect of:

Other services relating to taxation
2,430
2,225

All other services
3,000
3,000

Page 20

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

8.


Employees

Staff costs were as follows:


2024
2023
£
£

Wages and salaries
1,952,963
2,351,326

Social security costs
158,414
209,026

Cost of defined contribution scheme
143,762
172,606

2,255,139
2,732,958


The average monthly number of employees, including the directors, during the year was as follows:


        2024
        2023
            No.
            No.







Sales
13
25



Administration
21
21



Laboratory/Production
25
26

59
72


9.


Interest receivable

2024
2023
£
£


Other interest receivable
77,721
52,698

Page 21

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

10.


Taxation


2024
2023
£
£

Corporation tax


Current tax on profits for the year
-
(230,931)

Adjustments in respect of previous periods
(182,401)
148,213


(182,401)
(82,718)

Foreign tax


Foreign tax on income for the year
(7,767)
4,483

Total current tax
(190,168)
(78,235)

Deferred tax


Origination and reversal of timing differences
(77,714)
(48,091)

Total deferred tax
(77,714)
(48,091)


Taxation on loss on ordinary activities
(267,882)
(126,326)

Factors affecting tax charge for the year

The tax assessed for the year is higher than (2023 -higher than) the standard rate of corporation tax in the UK of 25% (2023 -25%). The differences are explained below:

2024
2023
£
£


Loss on ordinary activities before tax
(680,836)
(914,927)


Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2023 -25%)
(170,209)
(228,732)

Effects of:


Expenses not deductible for tax purposes
146
793

Adjustments to tax charge in respect of prior periods
(182,401)
(37,053)

Short term timing difference leading to an increase (decrease) in taxation
2,756
(47,534)

Other timing differences leading to an increase (decrease) in taxation
(8,323)
-

Adjustment in research and development tax credit leading to an increase (decrease) in the tax charge
20,843
8,467

Unrelieved tax losses carried forward
69,306
177,733

Total tax charge for the year
(267,882)
(126,326)

Page 22

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024
 
10.Taxation (continued)


Factors that may affect future tax charges

There is an unrecognised deferred tax asset of £69,306 relating to unutilised losses.


11.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Fixtures, fittings and equipment
Motor vehicles
Total

£
£
£
£
£



Cost or valuation


At 1 January 2024
729,761
248,463
1,226,382
15,486
2,220,092


Additions
680,853
369,963
30,274
-
1,081,090



At 31 December 2024

1,410,614
618,426
1,256,656
15,486
3,301,182



Depreciation


At 1 January 2024
537,027
207,629
1,064,883
12,389
1,821,928


Charge for the year
45,236
61,083
124,765
2,257
233,341



At 31 December 2024

582,263
268,712
1,189,648
14,646
2,055,269



Net book value



At 31 December 2024
828,351
349,714
67,008
840
1,245,913



At 31 December 2023
192,734
40,834
161,499
3,097
398,164

Page 23

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

12.


Intangible assets




Computer software

£



Cost


At 1 January 2024
247,993


Additions - internal
141,215



At 31 December 2024

389,208



Amortisation


At 1 January 2024
107,635


Charge for the year 
77,842



At 31 December 2024

185,477



Net book value



At 31 December 2024
203,731



At 31 December 2023
140,358




13.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


Additions
21,373



At 31 December 2024
21,373




Page 24

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

Subsidiary undertaking


The following was a subsidiary undertaking of the company:

Name

Registered office

Class of shares

Holding

Apollo Scientific GmbH
Kanalstraße 2, 41460 Neuss
Ordinary
100%

On 8 July 2024, Apollo Scientific GmbH was incorporated.


14.


Stocks

2024
2023
£
£

Raw materials and consumables
5,414,334
5,770,416

5,414,334
5,770,416


An impairment loss of £298,001 (2023 - £273,203) was recognised in cost of sales against stock during the year due to slow-moving and obsolete stock.

Page 25

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

15.


Debtors

2024
2023
£
£


Trade debtors
1,489,451
1,734,104

Amounts owed by group undertakings
33,621
452

Other debtors
392,525
539,448

Prepayments and accrued income
208,119
218,359

2,123,716
2,492,363



16.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
4,006,429
5,190,074



17.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
798,081
1,066,791

Amounts owed to group undertakings
31,374
179,545

Other taxation and social security
43,508
49,933

Other creditors
6,947
38,447

Accruals and deferred income
283,281
313,686

1,163,191
1,648,402



18.


Deferred taxation




2024
2023


£

£






At beginning of year
(77,714)
(125,805)


Charged to profit or loss
77,714
48,091



At end of year
-
(77,714)

Page 26

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024
 
18.Deferred taxation (continued)

The deferred taxation balance is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(225,232)
(77,436)

Tax losses carried forward
224,525
-

Other short-term timing differences
707
(278)

-
(77,714)


19.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



99 (2023 - 99 ) Ordinary shares of £1 each
99
99



20.


Reserves

Profit and loss account

The profit and loss account includes all current and prior period retained profits and losses.


21.


Pension commitments

The company operates a defined contribution pension scheme. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to £143,762 (2023 - £172,606). Contributions totalling £828 (2023 - £1,110) were payable to the fund at the balance sheet date and are included in creditors.


22.


Commitments under operating leases

At 31 December 2024 the company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£


Not later than 1 year
59,360
288,660

Later than 1 year and not later than 5 years
-
72,125

59,360
360,785

Page 27

 
Apollo Scientific Ltd
 
 
 
Notes to the financial statements
For the year ended 31 December 2024

23.


Related party transactions

Transactions entered into with companies wholly owned within the group have not been disclosed as permitted under FRS 102 paragraph 33.1A.
Key management personnel remuneration totalled £318,208 (
2023 - £400,242).


24.


Controlling party

The company is a wholly owned subsidiary of Central Glass Co. Ltd, a company incorporated in Japan and is listed on the Tokyo Stock Exchange (First Section) in Japan. Central Glass Co. Ltd  holds 100% of the issued share capital in Apollo Scientific Limited.
 
Page 28